Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Bamias, A. T. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Samantas, E. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Bamias, A. T. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:44Z | |
dc.date.available | 2018-06-22T09:52:44Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41480 | |
dc.description.abstract | The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. Successive cohorts of AS-SCLC patients were treated with irinotecan administered as a single 1-h infusion in combination with fixed doses of cisplatin (20 mg/m 2) and etoposide (75 mg/m2), both given for three consecutive days (ECI regimen). Irinotecan dose was escalated from 60 mg/m 2 by 40-mg/m2 increments. At mid-step between the maximum tolerated dose (MTD) and the previous dose level, patients were randomized for the day of administration of irinotecan (day 1 vs day 3). A total of 36 AS-SCLC patients received 166 courses of treatment at four dose levels. The MTD of irinotecan was 140 mg/m2 (three dose-limiting toxicities, DLTs), and the recommended optimal dose (ROD) 120 mg/m2 (two DLTs). DLTs were febrile neutropenia and grade 3 diarrhea. Other toxicities were mild. No difference in toxicity was seen between the two time schedules. A 77% (95% CI 63.25-90.75%) response rate was recorded among 31 evaluable patients and the median survival was 12 months. The ECI regimen was well tolerated and showed considerable activity in patients with AS-SCLC. Phase II/III evaluation is ongoing. © Springer-Verlag 2005. | en |
dc.language.iso | eng | en |
dc.source | Cancer chemotherapy and pharmacology | en |
dc.subject | Article | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Brain neoplasms | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer survival | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Cisplatin | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Drug infusion | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Multicenter study | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Etoposide | en |
dc.subject | Survival analysis | en |
dc.subject | Drug dose regimen | en |
dc.subject | Granulocyte colony stimulating factor | en |
dc.subject | Treatment outcome | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung small cell cancer | en |
dc.subject | Confidence interval | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Randomization | en |
dc.subject | Atropine | en |
dc.subject | Camptothecin | en |
dc.subject | Irinotecan | en |
dc.subject | Survival time | en |
dc.subject | Chemotherapy induced emesis | en |
dc.subject | Maximum tolerated dose | en |
dc.subject | Phase 1 clinical trial | en |
dc.subject | Liver neoplasms | en |
dc.subject | Granisetron | en |
dc.subject | Furosemide | en |
dc.subject | Small cell | en |
dc.subject | Phase i | en |
dc.subject | Bone neoplasms | en |
dc.subject | Cohort analysis | en |
dc.subject | Thrombosis | en |
dc.subject | Abdominal cramp | en |
dc.subject | Artery disease | en |
dc.subject | Asthenia | en |
dc.subject | Ischemia | en |
dc.subject | Small-cell lung cancer | en |
dc.title | Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s00280-004-0994-8 | |
dc.description.volume | 56 | |
dc.description.issue | 5 | |
dc.description.startingpage | 521 | |
dc.description.endingpage | 528 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-3286-778X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |